Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma

Journal of Postgraduate Medicine

Volumn 59, Issue 1, 2013, Pages 48-50

  Dubey, A K ^a   Dubey, S ^a   Handu, S S ^a   Qazi, M A ^a  

^a SHARDA UNIVERSITY   (India)

Author keywords

Basal cell carcinoma; hedgehog; vismodegib

Indexed keywords

PLACEBO; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTHRALGIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL ABSORPTION; HUMAN; HYPONATREMIA; LOW DRUG DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MUSCLE SPASM; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR REGRESSION; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PYRIDINES; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MLCS; MLOWN;

EID: 84881031844     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.109494     Document Type: Review

References (22)

1. Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, et al. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010;146:848-55
2. Ocanha JP, Dias JT, Miot HA, Stolf HO, Marques ME, Abbade LP. Relapses and recurrences of basal cell face carcinomas. An Bras Dermatol 2011;86:386-8
3. Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med 2012;366:2225-6
4. FDA News Release. FDA approves new treatment for most common type of skin cancer. Available from: Http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm289545.htm. [Last accessed on 2012 July 23].
5. Caro I, Low JA. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010;16:3335-9
6. Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001;10:757-62
7. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res 2009;69:6007-10
8. Fan H, Khavari PA. Sonic hedgehog opposes epithelial cell cycle arrest. J Cell Biol 1999;147:71-6
9. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8
10. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-81
11. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72
12. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11
13. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9
14. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8
15. Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:5774-82
16. Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011;17:2512-20
17. Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 2012;74:788-96
18. Erivedge (vismodegib) Label-FDA. Available from: Http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/203388lbl.pdf [Last accessed on 2012 Jul 23].
19. Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS One 2011;6:e27306
20. Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One 2011;6:e23943
21. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4
22. Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 2012;38:1863-6